New study tests if ofatumumab can protect nerves in MS patients

NCT ID NCT07353216

Recruiting now Disease control Sponsor: Third Affiliated Hospital, Sun Yat-Sen University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how well the drug ofatumumab works and how safe it is for people with relapsing multiple sclerosis (RMS) in China. Researchers will measure a nerve damage marker called sNfL in the blood to see if the drug helps protect nerves. About 80 adults with RMS will take part and be followed regularly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ofatumumab
What this could lead to: If successful, this study could confirm that ofatumumab effectively reduces nerve damage and relapses in Chinese patients with multiple sclerosis, supporting its use in this population.
What could go wrong: This is an observational study with only 80 participants, so results may not apply to all patients. It does not compare ofatumumab to other treatments, and long-term risks remain unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

The Third Affiliated Hospital of Sun Yat-sen University
RECRUITING

Guangzhou, Guangdong, 518000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.